Barinthus Biotherapeutics (BRNS) Operating Income (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Operating Income came in at -$6.1 million in Q1 2026, up 70.51% YoY from -$3.6 million in Q1 2025, and up 47.47% on a QoQ basis from -$11.6 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Operating Income (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Operating Income data on file, last reported at -$6.1 million in Q1 2026.
- Quarterly Operating Income rose 70.51% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.0 million (up 21.81% YoY) and the FY2025 annual result came in at -$70.6 million, down 3.8% from the prior year.
- Operating Income grew to -$6.1 million in Q1 2026, from -$11.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $13.2 million in Q2 2022 to a low of -$26.3 million in Q2 2023.
- A 5-year average of -$13.7 million and a median of -$16.9 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income jumped 230.71% — and 2023, when it tumbled 3385.02%.
- Tracing BRNS's Operating Income over 5 years: stood at -$25.1 million in 2022, then grew by 20.34% to -$20.0 million in 2023, then fell by 17.02% to -$23.4 million in 2024, then surged by 50.56% to -$11.6 million in 2025, then soared by 47.47% to -$6.1 million in 2026.
- The last three Operating Income figures came in at -$6.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -11.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.02 Mn |
| Mar 31, 2026 | -6.08 Mn |
| Dec 31, 2025 | -11.57 Mn |
| Sep 30, 2025 | -15.07 Mn |
| Jun 30, 2025 | -23.32 Mn |
| Mar 31, 2025 | -20.60 Mn |
| Dec 31, 2024 | -23.39 Mn |
| Sep 30, 2024 | -9.38 Mn |
| Jun 30, 2024 | -18.29 Mn |
| Mar 31, 2024 | -16.91 Mn |
| Dec 31, 2023 | -19.99 Mn |
| Sep 30, 2023 | -16.11 Mn |
| Jun 30, 2023 | -26.34 Mn |
| Mar 31, 2023 | -21.48 Mn |
| Dec 31, 2022 | -25.09 Mn |
| Sep 30, 2022 | 7.24 Mn |
| Jun 30, 2022 | 13.24 Mn |
| Mar 31, 2022 | 654,000.00 |
| Dec 31, 2021 | -16.67 Mn |
| Sep 30, 2021 | -5.54 Mn |